Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 48Rituximab 32fludarabine 29Doxorubicin 14Specimen Handling 13Magnetic Resonance Spectroscopy 13Vincristine 12Prednisone 12pirtobrutinib 11fludarabine phosphate 10Etoposide 10Bendamustine Hydrochloride 10Immunotherapy, Adoptive 9obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7pembrolizumab 7glofitamab 7zanubrutinib 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × sodium-iodide symporter × 1 year × Clear all
NCT03017820 2026-05-28

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
99 enrolled
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡